Business
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients73% of pegcetacoplan-treated patients achieved a
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) presented in oral session at 25th Congress of the European Hematology Association NDA and MAA submissions planned in H2 2020. Conference call scheduled today at 8:30 a.m. ET WALTHAM, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today presented detailed results from the Phase 3 PEGASUS study, which in January showed superiority (p","length":1553,"tagName":"div"}]